{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:58:55Z","timestamp":1792025935048,"version":"4.4.0"},"reference-count":68,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173677, 81773574"],"award-info":[{"award-number":["82173677, 81773574"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Key Project of NSFC for International Cooperation","award":["81420108027"],"award-info":[{"award-number":["81420108027"]}]},{"name":"the Shandong Provincial Key research and development project","award":["2019JZZY021011"],"award-info":[{"award-number":["2019JZZY021011"]}]},{"name":"Science Foundation for Outstanding Young Scholars of Shandong Province","award":["ZR2020JQ31"],"award-info":[{"award-number":["ZR2020JQ31"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Viral infections pose a persistent threat to human health. The relentless epidemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global health problem, with millions of infections and fatalities so far. Traditional approaches such as random screening and optimization of lead compounds by organic synthesis have become extremely resource- and time-consuming. Various modern innovative methods or integrated paradigms are now being applied to drug discovery for significant resistance in order to simplify the drug process. This review provides an overview of newly emerging antiviral strategies, including proteolysis targeting chimera (PROTAC), ribonuclease targeting chimera (RIBOTAC), targeted covalent inhibitors, topology-matching design and antiviral drug delivery system. This article is dedicated to Prof. Dr. Erik De Clercq, an internationally renowned expert in the antiviral drug research field, on the occasion of his 80th anniversary.<\/jats:p>","DOI":"10.3390\/molecules27030850","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T22:00:56Z","timestamp":1643320856000},"page":"850","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Newly Emerging Strategies in Antiviral Drug Discovery: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Anniversary"],"prefix":"10.3390","volume":"27","author":[{"given":"Shujing","family":"Xu","sequence":"first","affiliation":[{"name":"Key Laboratory of Chemical Biology (Ministry of Education), Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, Jinan 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dang","family":"Ding","sequence":"additional","affiliation":[{"name":"Key Laboratory of Chemical Biology (Ministry of Education), Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, Jinan 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1393-4665","authenticated-orcid":false,"given":"Xujie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Chemical Biology (Ministry of Education), Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, Jinan 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Sun","sequence":"additional","affiliation":[{"name":"Key Laboratory of Chemical Biology (Ministry of Education), Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, Jinan 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9232-953X","authenticated-orcid":false,"given":"Dongwei","family":"Kang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Chemical Biology (Ministry of Education), Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, Jinan 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boshi","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, 800 E Leigh Street, Richmond, VA 23298, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-2214","authenticated-orcid":false,"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Chemical Biology (Ministry of Education), Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, Jinan 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[{"name":"Key Laboratory of Chemical Biology (Ministry of Education), Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, Jinan 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.bcp.2012.12.011","article-title":"Antivirals: Past, present and future","volume":"85","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1021\/acs.jmedchem.9b00175","article-title":"Fifty Years in Search of Selective Antiviral Drugs","volume":"62","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrmicro975","article-title":"Antivirals and antiviral strategies","volume":"2","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Meyer, H., Ehmann, R., and Smith, G.L. (2020). Smallpox in the Post-Eradication Era. Viruses, 12.","DOI":"10.3390\/v12020138"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1086\/590567","article-title":"The 1918 \u201cSpanish flu\u201d in Spain","volume":"47","author":"Trilla","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.cell.2021.02.013","article-title":"Antivirals with common targets against highly pathogenic viruses","volume":"184","author":"Lu","year":"2021","journal-title":"Cell."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.chom.2020.03.014","article-title":"The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies","volume":"27","author":"Cohn","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.cell.2020.08.021","article-title":"Emerging Pandemic Diseases: How We Got to COVID-19","volume":"182","author":"Morens","year":"2020","journal-title":"Cell."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Gao, S., Huang, T., Song, L., Xu, S., Cheng, Y., Cherukupalli, S., Kang, D., Zhao, T., Sun, L., and Zhang, J. (2021). Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors. Acta. Pharm. Sin. B.","DOI":"10.1016\/j.apsb.2021.08.027"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/acs.jmedchem.5b00497","article-title":"Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends","volume":"59","author":"Zhan","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1039\/D0CS01084G","article-title":"Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses","volume":"50","author":"Ma","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9375","DOI":"10.1021\/acs.jmedchem.9b00359","article-title":"Overview of Recent Strategic Advances in Medicinal Chemistry","volume":"62","author":"Wu","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: An emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cbpa.2019.02.022","article-title":"Targeted protein degradation: Elements of PROTAC design","volume":"50","author":"Paiva","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1038\/s41467-019-11429-w","article-title":"Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations","volume":"10","author":"Du","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1073\/pnas.1914286117","article-title":"Small-molecule targeted recruitment of a nuclease to cleave an oncogenic RNA in a mouse model of metastatic cancer","volume":"117","author":"Costales","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.chembiol.2019.04.008","article-title":"Targeted Degradation of a Hypoxia-Associated Non-coding RNA Enhances the Selectivity of a Small Molecule Interacting with RNA","volume":"26","author":"Costales","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.1021\/jacs.8b01233","article-title":"Small Molecule Targeted Recruitment of a Nuclease to RNA","volume":"140","author":"Costales","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1021\/acscentsci.0c00984","article-title":"Targeting the SARS-CoV-2 RNA Genome with Small Molecule Binders and Ribonuclease Targeting Chimera (RIBOTAC) Degraders","volume":"6","author":"Haniff","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.drudis.2015.05.005","article-title":"Covalent inhibitors in drug discovery: From accidental discoveries to avoided liabilities and designed therapies","volume":"20","author":"Bauer","year":"2015","journal-title":"Drug Discov. Today"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1021\/acs.jmedchem.8b01153","article-title":"Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology","volume":"62","author":"Gehringer","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1039\/C7CS00220C","article-title":"Structure-based design of targeted covalent inhibitors","volume":"47","author":"Lonsdale","year":"2018","journal-title":"Chem. Soc. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9725","DOI":"10.1073\/pnas.1711463114","article-title":"Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: From design to protein crystallography","volume":"114","author":"Chan","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/nsmb.3271","article-title":"Cryomicroscopy provides structural snapshots of influenza virus membrane fusion","volume":"23","author":"Calder","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1021\/acscentsci.8b00666","article-title":"A Computational Assay that Explores the Hemagglutinin\/Neuraminidase Functional Balance Reveals the Neuraminidase Secondary Site as a Novel Anti-Influenza Target","volume":"4","author":"Amaro","year":"2018","journal-title":"ACS Cent. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"15532","DOI":"10.1002\/anie.202004832","article-title":"Topology-Matching Design of an Influenza-Neutralizing Spiky Nanoparticle-Based Inhibitor with a Dual Mode of Action","volume":"59","author":"Nie","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1021\/acs.nanolett.0c01723","article-title":"Spiky Nanostructures with Geometry-matching Topography for Virus Inhibition","volume":"20","author":"Nie","year":"2020","journal-title":"Nano. Lett."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"eabd3803","DOI":"10.1126\/sciadv.abd3803","article-title":"Heteromultivalent topology-matched nanostructures as potent and broad-spectrum influenza A virus inhibitors","volume":"7","author":"Nie","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"983","DOI":"10.4155\/fmc-2018-0053","article-title":"Learning from nature: The role of albumin in drug delivery","volume":"10","author":"Matos","year":"2018","journal-title":"Future Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1039\/C5CS00158G","article-title":"Simple bioconjugate chemistry serves great clinical advances: Albumin as a versatile platform for diagnosis and precision therapy","volume":"45","author":"Liu","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Chong, H., Yao, X., Zhang, C., Cai, L., Cui, S., Wang, Y., and He, Y. (2012). Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0032599"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1097\/CM9.0000000000001273","article-title":"Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: Interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study","volume":"133","author":"Su","year":"2020","journal-title":"Chin. Med. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"eabb0310","DOI":"10.1126\/sciadv.abb0310","article-title":"Cytosolic delivery of proteins by cholesterol tagging","volume":"6","author":"Tai","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nrd2400","article-title":"The war against influenza: Discovery and development of sialidase inhibitors","volume":"6","year":"2007","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"17403","DOI":"10.1021\/acs.jmedchem.1c01531","article-title":"Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses","volume":"64","author":"Lv","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e2111172118","DOI":"10.1073\/pnas.2111172118","article-title":"DNA-encoded chemistry technology yields expedient access to SARS-CoV-2 M(pro) inhibitors","volume":"118","author":"Chamakuri","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","article-title":"The promise and challenge of therapeutic genome editing","volume":"578","author":"Doudna","year":"2020","journal-title":"Nature."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"10266","DOI":"10.1002\/anie.202100225","article-title":"Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection","volume":"60","author":"Sun","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"13294","DOI":"10.1002\/anie.202102074","article-title":"Chemical Evolution of Antivirals Against Enterovirus D68 through Protein-Templated Knoevenagel Reactions","volume":"60","author":"Tauber","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Ekiert, H.M., and Szopa, A. (2020). Biological Activities of Natural Products. Molecules, 25.","DOI":"10.3390\/molecules25235769"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.4155\/fmc-2020-0084","article-title":"Medicinal chemistry strategies of targeting HIV-1 capsid protein for antiviral treatment","volume":"12","author":"Xu","year":"2020","journal-title":"Future Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"105142","DOI":"10.1016\/j.antiviral.2021.105142","article-title":"Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase","volume":"193","author":"Kasprzyk","year":"2021","journal-title":"Antiviral Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrmicro2820","article-title":"Viroporins: Structure and biological functions","volume":"10","author":"Nieva","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.abf4058","article-title":"Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A","volume":"371","author":"White","year":"2021","journal-title":"Science"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1517\/14728214.13.3.393","article-title":"Emerging antiviral drugs","volume":"13","year":"2008","journal-title":"Expert Opin. Emerg. Drugs."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.antiviral.2009.10.005","article-title":"In search of a selective therapy of viral infections","volume":"85","year":"2010","journal-title":"Antiviral Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1021\/jm900932g","article-title":"Highlights in the discovery of antiviral drugs: A personal retrospective","volume":"53","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-pharmtox-010510-100228","article-title":"A 40-year journey in search of selective antiviral chemotherapy","volume":"51","year":"2011","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/med.21256","article-title":"Highlights in antiviral drug research: Antivirals at the horizon","volume":"33","year":"2013","journal-title":"Med. Res. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.bcp.2013.07.012","article-title":"Dancing with chemical formulae of antivirals: A personal account","volume":"86","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/med.21340","article-title":"Curious discoveries in antiviral drug development: The role of serendipity","volume":"35","year":"2015","journal-title":"Med. Res. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.2174\/0929867322666150625094705","article-title":"Curious (Old and New) Antiviral Nucleoside Analogues with Intriguing Therapeutic Potential","volume":"22","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/rmv.1849","article-title":"Current treatment of hepatitis B virus infections","volume":"25","year":"2015","journal-title":"Rev. Med. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.apsb.2015.09.001","article-title":"An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964\u20132014","volume":"5","year":"2015","journal-title":"Acta. Pharm. Sin. B."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1021\/acs.jmedchem.8b01729","article-title":"Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles","volume":"62","author":"Huang","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"13604","DOI":"10.1021\/acs.jmedchem.1c00987","article-title":"Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies","volume":"64","author":"Huang","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1021\/acs.jmedchem.7b00332","article-title":"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants","volume":"60","author":"Kang","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"7991","DOI":"10.1021\/acs.jmedchem.6b00738","article-title":"Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles","volume":"59","author":"Kang","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.apsb.2019.08.013","article-title":"Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs","volume":"10","author":"Kang","year":"2020","journal-title":"Acta Pharm. Sin. B."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1021\/acs.jmedchem.0c00117","article-title":"Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties","volume":"63","author":"Kang","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1021\/acs.jmedchem.9b01769","article-title":"Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel","volume":"63","author":"Kang","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1021\/acs.jmedchem.1c00268","article-title":"2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies","volume":"64","author":"Kang","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1021\/acs.jmedchem.8b01656","article-title":"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties","volume":"62","author":"Kang","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1021\/acs.jmedchem.0c00015","article-title":"Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities","volume":"63","author":"Sun","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"13658","DOI":"10.1021\/acs.jmedchem.1c01015","article-title":"Discovery of Novel Dihydrothiopyrano[4,3-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs with Significantly Reduced hERG Inhibitory Activity and Improved Resistance Profiles","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/3\/850\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:09:14Z","timestamp":1760134154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/3\/850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":68,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["molecules27030850"],"URL":"https:\/\/doi.org\/10.3390\/molecules27030850","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]}}}